Jun 15, 2017 • 7:05 am EDT Corbus Pharmaceuticals Presented Data from Phase 2 Study of Anabasum for the Treatment of Systemic Sclerosis at the EULAR 2017 Annual Meeting
Jun 8, 2017 • 9:10 am EDT Corbus Pharmaceuticals to Present Data from Phase 2 Study of Anabasum at the European Cystic Fibrosis Society 2017 Conference
Jun 1, 2017 • 7:30 am EDT Corbus Pharmaceuticals to Present at the 2017 Jefferies Global Healthcare Conference
May 11, 2017 • 8:00 am EDT Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Anabasum for the Treatment of Skin-Predominant Dermatomyositis
May 9, 2017 • 9:00 am EDT Corbus Pharmaceuticals Reports 2017 First Quarter Financial Results and Provides Business Update
Apr 5, 2017 • 8:30 am EDT Corbus Pharmaceuticals to Commence Single Phase 3 Study of Anabasum for Treatment of Systemic Sclerosis Following Guidance Received from Successful End-of-Phase 2 Meeting with FDA
Mar 30, 2017 • 6:00 am EDT Corbus Pharmaceuticals Reports Positive Topline Data Demonstrating Anabasum Reduces Acute Pulmonary Exacerbations and Multiple Inflammatory Biomarkers in Phase 2 Study in Patients with Cystic Fibrosis
Mar 9, 2017 • 7:00 am EST Corbus Pharmaceuticals Reports 2016 Financial Results and Provides 2017 Business Update
Mar 8, 2017 • 8:00 am EST Corbus Pharmaceuticals to Present Gene Expression Data from Recent Phase 2 Systemic Sclerosis Study Demonstrating JBT-101 Inhibits Inflammation and Fibrosis Pathways